Table 2.
Impact of missing deaths on measures of absolute risk (mOS)
| Median Overall Survival and 95% CI, mo | |||||||
|---|---|---|---|---|---|---|---|
| Exposure Group | Simulation 1 (63.4%) | Bias, % | Simulation 2 (72.5%) | Bias, % | EHR‐derived (90.6%) | Bias, % | Gold Standard Data |
| Platinum treatment | 12.3 (11.7‐13.0) | 36.7 | 11.2 (10.7‐11.7) | 24.4 | 9.5 (9.1‐9.9) | 5.6 | 9.0 (8.7‐9.4) |
| Other Chemo | 11.8 (10.1‐13.6) | 53.2 | 10.1 (8.8‐11.9) | 31.2 | 8.2 (7.3‐9.6) | 6.5 | 7.7 (6.9‐8.7) |
| EGFR+ | 20.7 (17.8‐25.9) | 46.8 | 19.4 (15.9‐22.2) | 37.6 | 15.0 (13.4‐18.9) | 6.4 | 14.1 (12.1‐17.3) |
| EGFR‐ | 21.2 (18.9‐25.3) | 43.2 | 19.2 (17.1‐21.4) | 29.7 | 16.0 (14.5‐18.3) | 8.1 | 14.8 (14.0‐17.0) |
| KRAS+ | 33.4 (28.5‐NA) | 40.9 | 29.9 (24.9‐36.2) | 25.8 | 24.3 (22.3‐29.4) | 2.5 | 23.7 (21.7‐27.3) |
| KRAS‐ | 16.3 (15.2‐17.2) | 39.3 | 14.6 (13.9‐15.3) | 24.8 | 12.4 (11.8‐13.1) | 6.0 | 11.7 (11.3‐12.4) |